Mode
Text Size
Log in / Sign up
N/A N=337 Randomized Diagnostic

Telemedicine in High-Risk Cardiovascular Patients Post-ACS

Cardiovascular Diseases · Acute Coronary Syndrome

Enrolled (actual)
337
Serious AEs
14.5%
Results posted
Feb 2026
Primary outcome: Primary: Number of Participants With Hospital Readmission at 6 Months — 13; 48 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active Arm (Other); Control Arm (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Imperial College London
Primary completion
Feb 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Hospital Readmission at 6 Months
13; 48
PRIMARY
Emergency Department Visits at 6 Months
39; 62
SECONDARY
Length of Stay
1.2; 1.8
SECONDARY
All-cause Mortality
1.2; 1.2
SECONDARY
Number of Participants With Major Adverse Cardiac Events (MACE) at 9 Months
17; 21
SECONDARY
Medical Intervention
4; 15
SECONDARY
9 Months Readmission Rates
20; 50
SECONDARY
Patient-Reported Quality of Life - 3 Months
67.5; 68.9; 57.5; 52.5; 63.7; 60.0
SECONDARY
Patient-Reported Quality of Life - 6 Months
73.0; 70.6; 65.9; 63.0; 70.0; 71.0
SECONDARY
Patient-Reported Quality of Life - 9 Months
75.5; 69.5; 71.2; 59.2; 79.0; 66.2

Summary

This is a non-CTIMP randomised controlled trial looking at the utilisation of telemedicine devices to provide remote, clinically necessary, diagnostic information, without the need for hospital attendance that patients will take home with them following admission to hospital with a heart attack.

Eligibility Criteria

Inclusion Criteria

  • 1 ACS Patients diagnosed with elevated hs-cTnI I who have undergone coronary intervention for NSTEMI or STEMI or unstable angina.
  • 2 In addition, the participant should have at least one additional cardiovascular risk factor:
  • Current or ex-Tobacco Use
  • Hypertension
  • Diabetes
  • Hypercholesterolaemia.
  • Male aged > 50 years.
  • 3 Access to a smartphone or smart device.

Exclusion Criteria

  • 1 The inability to apply/use the telemonitoring equipmentt
  • 2 Life expectancy of 9 months or less.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05015634). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search